PEGylated Recombinant Aplysia punctata Ink Toxin Depletes Arginine and Lysine and Inhibits the Growth of Tumor Xenografts

In recent years, a novel treatment method for cancer has emerged, which is based on the starvation of tumors of amino acids like arginine. The deprivation of arginine in serum is based on enzymatic degradation and can be realized by arginine deaminases like the l-amino acid oxidase found in the ink...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS biomaterials science & engineering 2024-06, Vol.10 (6), p.3825-3832
Hauptverfasser: Wolkersdorfer, Alena M., Bergmann, Birgit, Adelmann, Juliane, Ebbinghaus, Matthias, Günther, Eckhard, Gutmann, Marcus, Hahn, Lukas, Hurwitz, Robert, Krähmer, Ralf, Leenders, Frank, Lühmann, Tessa, Schueler, Julia, Schmidt, Luisa, Teifel, Michael, Meinel, Lorenz, Rudel, Thomas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In recent years, a novel treatment method for cancer has emerged, which is based on the starvation of tumors of amino acids like arginine. The deprivation of arginine in serum is based on enzymatic degradation and can be realized by arginine deaminases like the l-amino acid oxidase found in the ink toxin of the sea hare Aplysia punctata. Previously isolated from the ink, the l-amino acid oxidase was described to oxidate the essential amino acids l-lysine and l-arginine to their corresponding deaminated alpha-keto acids. Here, we present the recombinant production and functionalization of the amino acid oxidase Aplysia punctata ink toxin (APIT). PEGylated APIT (APIT–PEG) increased the blood circulation time. APIT–PEG treatment of patient-derived xenografted mice shows a significant dose-dependent reduction of tumor growth over time mediated by amino acid starvation of the tumor. Treatment of mice with APIT–PEG, which led to deprivation of arginine, was well tolerated.
ISSN:2373-9878
2373-9878
DOI:10.1021/acsbiomaterials.4c00473